奈玛特韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "奈玛特韦" in Chinese language version.

refsWebsite

Global rank Chinese rank

13web.archive.org

1^st place

7doi.org

2^nd place

23^rd place

6nih.gov

4^th place

5^th place

2worldcat.org

5^th place

12^th place

2pfizer.com

low place

7,863^rd place

2fda.gov

447^th place

581^st place

2mingpao.com

876^th place

33^rd place

1nmpa.gov.cn

low place

6,139^th place

1who.int

195^th place

179^th place

1acs.org

1,248^th place

434^th place

1clinicaltrials.gov

5,225^th place

4,888^th place

1clinicaltrialsarena.com

low place

1archive.today

14^th place

18^th place

1nationalpost.com

818^th place

1,332^nd place

1racgp.org.au

low place

1stcn.com

low place

941^st place

acs.org

cen.acs.org

Halford, Bethany. Pfizer unveils its oral SARS-CoV-2 inhibitor. Chemical & Engineering News. 2021-04-07 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.

archive.today

Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19. The Telegraph. 26 April 2021. （原始内容存档于27 April 2021） –通过National Post （英语）.

clinicaltrials.gov

Pfizer. A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19. 2021-06-23 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.

clinicaltrialsarena.com

Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19.. Clinical Trials Arena. 2 September 2021 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.

doi.org

Dragovich, Peter S.; Prins, Thomas J.; Zhou, Ru; Webber, Stephen E.; Marakovits, Joseph T.; Fuhrman, Shella A.; Patick, Amy K.; Matthews, David A.; Lee, Caroline A. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements. Journal of Medicinal Chemistry. 1999-04-01, 42 (7): 1213–1224. ISSN 0022-2623. doi:10.1021/jm9805384 （英语）.
Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry. 2016-07-28, 59 (14): 6595–6628. ISSN 0022-2623. PMC 7075650 . PMID 26878082. doi:10.1021/acs.jmedchem.5b01461 （英语）.
Pedersen, Niels C.; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C.; Eckstrand, Chrissy; Groutas, William C.; Bannasch, Michael; Meadows, Juliana M.; Chang, Kyeong-Ok. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2018, 20 (4): 378–392. PMC 5871025 . PMID 28901812. doi:10.1177/1098612X17729626 （英语）.
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006 （英语）.
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrobial Agents and Chemotherapy. September 2021, 65 (10): e0115521. PMID 34310217. doi:10.1128/AAC.01155-21 （英语）.
Antiviral treatment of COVID-19: An update. Turkish Journal of Medical Sciences. August 2021. PMID 34391321. doi:10.3906/sag-2106-250 （英语）.
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. August 2021, 22 (17): 9124. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124 （英语）.

fda.gov

《Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 （页面存档备份，存于互联网档案馆）》（美国食品药品监督管理局新聞發佈，2021年12月22日）
《EUA 105 Pfizer Paxlovid LOA (12222021) - US Food and Drug Administration （页面存档备份，存于互联网档案馆）》

mingpao.com

news.mingpao.com

治療新冠病毒輝瑞口服藥首批今抵港　港府已購入足夠口服藥. 明報. 2022-03-15 [2022-03-15]. （原始内容存档于2022-04-18）.
需發病5天內服預約指定診所或逾一周輝瑞藥抵港團體憂求診難失時機. 明報. [2022-03-15]. （原始内容存档于2022-06-14）.

nationalpost.com

Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19. The Telegraph. 26 April 2021. （原始内容存档于27 April 2021） –通过National Post （英语）.

nih.gov

ncbi.nlm.nih.gov

Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry. 2016-07-28, 59 (14): 6595–6628. ISSN 0022-2623. PMC 7075650 . PMID 26878082. doi:10.1021/acs.jmedchem.5b01461 （英语）.
Pedersen, Niels C.; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C.; Eckstrand, Chrissy; Groutas, William C.; Bannasch, Michael; Meadows, Juliana M.; Chang, Kyeong-Ok. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. Journal of Feline Medicine and Surgery. 2018, 20 (4): 378–392. PMC 5871025 . PMID 28901812. doi:10.1177/1098612X17729626 （英语）.
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006 （英语）.
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrobial Agents and Chemotherapy. September 2021, 65 (10): e0115521. PMID 34310217. doi:10.1128/AAC.01155-21 （英语）.
Antiviral treatment of COVID-19: An update. Turkish Journal of Medical Sciences. August 2021. PMID 34391321. doi:10.3906/sag-2106-250 （英语）.
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International Journal of Molecular Sciences. August 2021, 22 (17): 9124. PMC 8430524 . PMID 34502033. doi:10.3390/ijms22179124 （英语）.

nmpa.gov.cn

国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册. 国家药品监督管理局. 2022-02-12 [2022-02-12]. （原始内容存档于2022-05-16）.

pfizer.com

Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. 5 Nov 2021 [2021-11-05]. （原始内容存档于2021-11-16）（英语）.
《Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment （页面存档备份，存于互联网档案馆）》（輝端公司新聞稿，2021年12月22日）

racgp.org.au

www1.racgp.org.au

What is Australia’s potential new COVID treatment?. The Royal Australian College of General Practitioners (RACGP). 19 Oct 2021 [6 November 2021]. （原始内容存档于2021-11-05）（英语）.

stcn.com

kuaixun.stcn.com

以色列批准紧急使用辉瑞抗新冠口服药. [2021-12-27]. （原始内容存档于2022-05-16）.

web.archive.org

国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册. 国家药品监督管理局. 2022-02-12 [2022-02-12]. （原始内容存档于2022-05-16）.
WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator. 世衛組織. 2022-04-22 [2022-04-25]. （原始内容存档于2022-06-11）.
Halford, Bethany. Pfizer unveils its oral SARS-CoV-2 inhibitor. Chemical & Engineering News. 2021-04-07 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.
Pfizer. A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19. 2021-06-23 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.
Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19.. Clinical Trials Arena. 2 September 2021 [2021-11-05]. （原始内容存档于2021-11-05）（英语）.
What is Australia’s potential new COVID treatment?. The Royal Australian College of General Practitioners (RACGP). 19 Oct 2021 [6 November 2021]. （原始内容存档于2021-11-05）（英语）.
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study. 5 Nov 2021 [2021-11-05]. （原始内容存档于2021-11-16）（英语）.
《Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment （页面存档备份，存于互联网档案馆）》（輝端公司新聞稿，2021年12月22日）
《Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 （页面存档备份，存于互联网档案馆）》（美国食品药品监督管理局新聞發佈，2021年12月22日）
《EUA 105 Pfizer Paxlovid LOA (12222021) - US Food and Drug Administration （页面存档备份，存于互联网档案馆）》
以色列批准紧急使用辉瑞抗新冠口服药. [2021-12-27]. （原始内容存档于2022-05-16）.
治療新冠病毒輝瑞口服藥首批今抵港　港府已購入足夠口服藥. 明報. 2022-03-15 [2022-03-15]. （原始内容存档于2022-04-18）.
需發病5天內服預約指定診所或逾一周輝瑞藥抵港團體憂求診難失時機. 明報. [2022-03-15]. （原始内容存档于2022-06-14）.

who.int

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator. 世衛組織. 2022-04-22 [2022-04-25]. （原始内容存档于2022-06-11）.

worldcat.org

Dragovich, Peter S.; Prins, Thomas J.; Zhou, Ru; Webber, Stephen E.; Marakovits, Joseph T.; Fuhrman, Shella A.; Patick, Amy K.; Matthews, David A.; Lee, Caroline A. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements. Journal of Medicinal Chemistry. 1999-04-01, 42 (7): 1213–1224. ISSN 0022-2623. doi:10.1021/jm9805384 （英语）.
Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun. An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Journal of Medicinal Chemistry. 2016-07-28, 59 (14): 6595–6628. ISSN 0022-2623. PMC 7075650 . PMID 26878082. doi:10.1021/acs.jmedchem.5b01461 （英语）.